SAN FRANCISCO, Sept 24 Lightstone Ventures, a firm formed by life-sciences partners at Morgenthaler Ventures and Advanced Technology Ventures, is raising a fund of at least $200 million.
The fund will focus on early-stage therapeutics, said a source, who did not want to be identified because of Securities and Exchange Commission regulations governing advertising of private funds. Those rules are currently being revised.
Last year, Morgenthaler and ATV told their investors they planned to spin off their life sciences teams and merge them, amid a challenging environment for life sciences. The partners will stay involved in the existing life-sciences and health investments at those firms, the person said, but new investments will be made from Lightstone.
Some venture capitalists see signs to be more positive about life sciences, including a handful of big acquisitions and a potentially speedier path to drug approval in some cases.
Fininvest says to challenge ECB decision on Mediolanum stake in court
MILAN, Oct 28 Italy's Fininvest said on Friday it will challenge in court a decision by the European Central Bank that could force it to reduce its 30 percent stake in asset gatherer Banca Mediolanum.
Fitch Revises 4 Italian Banks' Outlooks to Negative on Sovereign Outlook Revision
(The following statement was released by the rating agency) MILAN/LONDON, October 28 (Fitch) Fitch Ratings has revised the Outlooks of Intesa Sanpaolo (IntesaSP), Credito Emiliano (Credem), Mediobanca and Banca Nazionale del Lavoro (BNL) to Negative from Stable while affirming their Long- and Short-Term Issuer Default Ratings (IDRs). A full list of rating actions is available at the end of this rating action commentary. The four banks' Outlook revision to Negative follows the revision of Ita